TheraRadar
Clinical-Stage Companies / Asklepion

Asklepion

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 7/25/2025

6
Total Trials
3
Phase 3
3
Phase 2
0
Recruiting
75
Score

Pipeline by Phase

Phase 3
3
Phase 2
3
Phase 1
2

Therapeutic Focus

Ventricular Septal Defect Atrioventricular Septal Defect Sickle Cell Disease Primum Atrial Septal Defect Acute Vaso Occlusive Crisis (VOC)

Clinical Trials (6)

NCT06989567 Phase 3 NOT YET RECRUITING

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Started: 7/25/2025

NCT05253209 Phase 3 TERMINATED

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Started: 6/29/2022

NCT02891837 Phase 3 COMPLETED

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

Started: 8/1/2016

NCT04570384 Phase 2 COMPLETED

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

Started: 10/15/2020

NCT04852172 Phase 1 TERMINATED

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

Started: 4/29/2021

NCT01120964 Phase 1 COMPLETED

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

Started: 9/1/2010

Drug Candidates

L-citrulline Plasmalyte A L-Citrulline Intravenous L-Citrulline
Activity Status: Slowing
Last Trial Started: 7/25/2025
Last Trial Ended: 5/10/2024
Trials (12 months): 0
Completed Trials: 3
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.